Skip to main content

Table 3 Comparison of variables between patients with DAH receiving PLEX and those not receiving

From: Clinical implication of plasma exchange on life-threatening antineutrophil cytoplasmic antibody-associated vasculitis

Variables

Patients with DAH not receiving PLEX (N = 4)

Patients with DAH receiving PLEX (N = 6)

P value

Demographic data at DAH

 Age (years)

56.5 (21.0)

65.5 (34.0)

0.807

 Male gender (N, (%))

2 (50.0)

3 (50.0)

1.000

MPA vs. GPA (N, (%))

3 (75.0)

4 (66.7)

0.778

ANCA within 4 weeks before DAH (N, (%))

 MPO-ANCA

3 (75.0)

2 (33.3)

0.197

 PR3-ANCA

1 (25.0)

2 (33.3)

0.778

 ANCA negativity

0 (0)

2 (33.3)

0197

AAV related indices at DAH

 BVAS

16.0 (17.0)

15.0 (13.5)

1.000

 FFS

2.0 (0)

2.5 (2.25)

1.000

Steroid pulse at DHA (N, (%))

4 (100)

6 (100)

N/A

Administered immunosuppressive drugs (N, (%))

 CYC

4 (100)

5 (83.3)

0.389

 RTX

0 (0)

2 (33.3)

0.197

 AZA

3 (75.0)

1 (16.7)

0.065

 MMF

0 (0)

2 (33.3)

0.197

 TAC

0 (0)

1 (16.7)

0.389

 None

0 (0)

1 (16.7)

0.389

Follow-up duration (days)

1145.5 (3421.5)

130.0 (291.8)

0.080

All-cause mortality (N, (%))

1 (25.0)

3 (50.0)

0.429

  1. Values are expressed as median (interquartile range (IQR)) or number (percentage)
  2. DAH diffuse alveolar haemorrhage, PLEX plasma exchange, MPA microscopic polyangiitis, GPA granulomatosis with polyangiitis, ANCA antineutrophil cytoplasmic antibody, MPO myeloperoxidase, PR3 proteinase 3, AAV antineutrophil cytoplasmic antibody-associated vasculitis, BVAS Birmingham vasculitis activity score, FFS five factor score, CYC cyclophosphamide, RTX rituximab, AZA azathioprine, MMF mycophenolate mofetil, TAC tacrolimus